World
WHO Advises Doctors Not to Use Gilead’s Remdesivir for Covid
- U.S. FDA recently approved the drug for hospitalized patients
- WHO experts say no evidence remdesivir improves survival
This article is for subscribers only.
The World Health Organization recommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal.